Alumis (ALMS) Liabilities and Shareholders Equity (2023 - 2025)
Alumis' (ALMS) quarterly Liabilities and Shareholders Equity came in at $411.9 million in Q4 2025, up 20.81% year-on-year from $341.0 million in Q4 2024, and down 15.59% on a QoQ basis from $488.0 million in Q3 2025.
Alumis (ALMS) Liabilities and Shareholders Equity (2023 - 2025) Analysis & Trends
Alumis (ALMS) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $411.9 million in Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity rose 20.81% year-over-year to $411.9 million in Q4 2025; TTM through Dec 2025 was $1.8 billion, a 73.96% increase from a year earlier, with the FY2025 full-year figure at $411.9 million, up 20.81% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $411.9 million, down from $488.0 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for ALMS reached as high as $610.9 million in Q2 2025 and fell as low as $89.6 million in Q4 2023.
- Historically, Liabilities and Shareholders Equity has averaged $360.1 million across 3 years, with a median of $376.5 million in 2024.
- Across the five-year window, Liabilities and Shareholders Equity soared 280.52% in 2024 and advanced 18.29% in 2025, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $89.6 million in 2023, then surged by 280.52% to $341.0 million in 2024, then rose by 20.81% to $411.9 million in 2025.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $411.9 million in Q4 2025, $488.0 million in Q3 2025, and $610.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Alumis | 2.41 Bn | 2.10 Bn | - | 411.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 411.94 Mn |
| Sep 30, 2025 | 488.01 Mn |
| Jun 30, 2025 | 610.93 Mn |
| Mar 31, 2025 | 261.30 Mn |
| Dec 31, 2024 | 340.99 Mn |
| Sep 30, 2024 | 412.56 Mn |
| Jun 30, 2024 | 265.18 Mn |
| Dec 31, 2023 | 89.61 Mn |